Navigation Links
PAREXEL International Announces 2-For-1 Stock Split
Date:2/11/2008

BOSTON, Feb. 11 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) announced today that its Board of Directors has approved a 2-for-1 split of its Common Stock, which will be effected by means of a 100% stock dividend.

Holders of PAREXEL's Common Stock will receive one additional share of Common Stock for each share of Common Stock held on the record date of February 22, 2008. The additional shares will be distributed on or about March 3, 2008 by PAREXEL's transfer agent, Computershare Trust Company, N.A., and trading of PAREXEL shares on a split-adjusted basis will begin on March 4, 2008.

As of February 8, 2008, PAREXEL had approximately 28.4 million shares of Common Stock outstanding. Following the stock split, the number of outstanding shares of Common Stock will increase to approximately 56.8 million.

Josef von Rickenbach, Chairman and CEO stated, "The stock split reflects the confidence that we have for PAREXEL's future growth prospects and opportunities. We believe this action will serve to attract a broader base of investors by making our stock more accessible, while at the same time further improving liquidity."

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clini
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
2. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
3. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
4. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
5. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
6. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
7. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
8. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
9. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Cryo-Cell International, Inc. Reports Results for Fiscal 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...3/PRNewswire/--Frost&Sullivan,theGrowthPartner...tingleadershipandinnovationThursday,November19,200...theldinSanAntonio,Texas. ,, (Logo: http://www.n...eHealthcareInnovationAwardsaregiventocompaniesthat...nagementofhealthcare.Suchcompanieshaveshownsuccess...
(Date:11/23/2009)...re-FirstCall/--CornerstoneTherapeuticsInc.(Nasdaq:...quiring,developingandcommercializingsignificantpro...odayannouncedthatCraigA.Collard,PresidentandChiefE...atthe21stAnnualPiperJaffrayHealthCareConferenceat3...eHotelinNewYorkCity. ,, Aliveaudioandarchivedwe...
(Date:11/20/2009)...ies have an opportunity to take the lead in two sm...iversity of Valencia (UV), working together with t... fabric of the Spanish biotechnology industry. The...rs have more clout than those in English-speaking ...d plants has been overlooked by the leading countr...
(Date:11/20/2009)...ewswire-FirstCall/ -- Dendreon Corporation (Nasdaq...rug Administration (FDA) provided written acknowle...se Application (BLA) for PROVENGE® (sipuleuce... a Prescription Drug User Fee Act (PDUFA) date of ...reon,s amended BLA. Dendreon is seeking licensure...
Breaking Biology Technology:Excellence in Healthcare Innovation Recognized by Frost & Sullivan 2Excellence in Healthcare Innovation Recognized by Frost & Sullivan 3Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Spanish biotechnology should focus on food and plant sectors to be more competitive 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3
...l 25 CV Therapeutics,Inc. (Nasdaq: CVTX ) today ...nded March 31, 2008., For the quarter ended March...9 million, or $0.53 per share. This compares to a ... the prior quarter ended December 31, 2007,and $55...er in 2007., For the quarter ended March 31, 2008...
...ntists and Collaborators Publish Study in Science,...bH, the,leading developer of RAFT intervention the...per in Science demonstrating a potential novel str...and other diseases by targeting,discrete sub-compa...nducted,by JADO scientists together with several a...
...lif., April 24 ,Exelixis, Inc. (Nasdaq: EXEL ) an...t and chief executive officer of Exelixis, will pr...ugged Conference at 3:40 p.m. ET/12:40,p.m. PT on ...s updates to,the company,s development pipeline an...ebcast and may be accessed in the Event,Calendar p...
Other Biology Technology:CV Therapeutics Reports 2008 First Quarter Financial Results 2CV Therapeutics Reports 2008 First Quarter Financial Results 3CV Therapeutics Reports 2008 First Quarter Financial Results 4CV Therapeutics Reports 2008 First Quarter Financial Results 5Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 2Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 3Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 4
(Date:11/24/2009)...akened and flabby arteries from collapsing have be...tents are no longer needed -- once the arteries ar...y, doctors had no choice but to leave them in plac...ty,s Department of Biomedical Engineering has deve...ries drugs where they,re needed, then dissolves. ,...
(Date:11/24/2009)...rctica has long held secrets of the earth,s histor...ere has been very little information on the enviro...for millions of years. Now, a team of researchers ...unded to the tune of $10 million dollars by the Na...ottom of things literally. These scientists will ...
(Date:11/23/2009)...rch presents strong evidence that the "synergistic...affic-related pollution and indoor endotoxin cause...her exposure alone. , Environmental health sci...ge of Medicine have shown that children exposed to... indoor endotoxin during early life are six times ...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile 59967 1Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile 59967 2Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile 59967 3Rotavirus Vaccine Cutting Infection Rates Among Kids 59964 1Rotavirus Vaccine Cutting Infection Rates Among Kids 59964 2Syphilis survey reveals need for accurate testing for early infection 59960 1
...r an important and longstanding question about the...tients have high levels of a brain protein because...ear it from their brains quickly enough? , Resear... (ADRC) at Washington University School of Medicin...ensitive way to monitor the production and clearan...
...ered that a recently identified protein critical f...sm to keep its repairs accurate. , The protein, ... proteins known as DNA polymerases that are vital ...while other DNA-repair proteins insure their accur...ns or accessory molecules, this protein maintains ...
...asbro Children’s Research Center and Brown Medical...atest risk for HIV. Amongst a group of high-risk t... for the disease (those who engaged in the most un...ental health problems. , Prior studies have found ...h mental health issues and other high-risk behavio...
Other Biology News:Production of key Alzheimer's protein monitored for first time in humans 2Production of key Alzheimer's protein monitored for first time in humans 3Unusual mechanism keeps repair protein accurate 2Unusual mechanism keeps repair protein accurate 3New HIV study identifies high-risk subgroups of adolescents 2New HIV study identifies high-risk subgroups of adolescents 3
Rabbit Anti-NMDAR1 C2' Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Coronin / CORO1C Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-Human Retinoic Acid-Induced 3 (RAI3 / RAIG1) Polyclonal Antibody, Unconjugated from IMGENEX
GIBCO Sf-900 Medium (1.3X) liquid from Invitrogen
Biology Products: